

# Oral GLP1 in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embolic Trial)

Study location [BCDiabetes: 400 - 210 West Broadway, Vancouver V5Y 3W2](#)

Principal Investigators Dr. Tom Elliott

SubInvestigators : Dr Dale Clayton and Dr Dae Won (David) Lee

SC & Primary Contact Marla Inducil MD P: 604-628-7253 x 7011 : [minducil@bcdiabetes.ca](mailto:minducil@bcdiabetes.ca)

Back up SC: Hector Com MD ; Glaiza Erfe MD; Alireza Moshiri MD

**Summary:** This trial covers 2 independent Phase III pivotal studies, D7260C00015-Study 1 (hereafter referred to as “Study 1”) and D7260C00015-Study 2 (hereafter referred to as “Study 2”), to evaluate the efficacy and safety of eleoglipron compared with placebo in:

- Study 1: Participants living with obesity or overweight with at least one weight-related comorbidity (hypertension, prediabetes, dyslipidemia, cardiovascular disease, obstructive sleep apnea) and without type 2 diabetes mellitus (T2DM)
- Study 2: Participants living with obesity or overweight with T2DM


## Hypothesis:

### Eligible Participants include:

- Male or female  $\geq 18$  yrs of age
- Study 1 - Overweight ( BMI  $\geq 30$ ) or BMI  $25 \text{ kg/m}^2 \leq \text{BMI} < 30 \text{ kg/m}^2$  + 1 comorbidity
- Study 2 - Overweight ( BMI  $\geq 25$ ) with T2DM treated with diet and exercise or OHA OR without T2 DM and A1c  $\geq 6.5\%$ ; Participants with HbA1c  $< 8.5\%$  may proceed with randomization provided all other criteria met; Participants with A1c  $> 8.5\%$  and overt signs/symptoms of hyperglycemia must be rescreened after a 90-day period, during which they should receive standard of care glucose management except GLP-1 RA containing medications.

**Treatment course and duration:** The estimated maximum study follow-up for participants is approximately 2.5 yrs.

**Odds of receiving active drug are:** 1:1:1 (45mg:65 mg:pbo)



## Study documents:

Short URL = <https://bit.ly/4vYChDo>